Revision: April 27, 2022, 3 p.m.
Health and Human Services
April 27, 2022
2022-1867s
05/04
Amendment to HB 1022
Amend the title of the bill by replacing it with the following:
AN ACT permitting pharmacists to dispense the drug Ivermectin by means of a standing order and establishing a commission to study the use of Ivermectin to treat Covid-19.
Amend RSA 318-47-n, I as inserted by section 1 of the bill by replacing it with the following:
I. In this section, "standing order" means a written and signed protocol authored by one or
more physicians licensed under RSA 329:12 or one or more advanced practice registered nurses licensed under RSA 326-B:18. Such agreement shall specify a protocol allowing the pharmacist licensed under RSA 318:18 to dispense Ivermectin under the delegated prescriptive authority of the physician or advanced practice registered nurse, specify a screening protocol for each patient, specify a requirement to document screening performed and the prescription in the patient's medical record, and include a plan for referring for evaluation and treatment of adverse events; provided that the standing order shall not be used if the patient is pregnant or under 18 years of age. Any such prescription shall be regarded as being issued for a legitimate medical purpose in the usual course of professional practice.
Amend the bill by replacing all after section 4 with the following:
5 New Subdivision; Commission to Study the Use of Ivermectin to Treat Covid-19 Established. Amend RSA 126-A by inserting after section 97 the following new subdivision:
Commission to Study the Use of Ivermectin to Treat Covid-19
126-A:98 Commission to Study the Use of Ivermectin to Treat Covid-19. There is established a commission to study use of Ivermectin to treat Covid-19.
I. The members of the commission shall be as follows:
(a) Three members of the house of representatives, appointed by the speaker of the house of representatives, at least one of whom shall be a member of the house health, human services and elderly affairs committee and one of whom shall be a member of the executive departments and administration committee.
(b) One member of the senate, appointed by the president of the senate.
(c) The commissioner of the department of health and human services, or designee.
(d) A representative of the New Hampshire board of pharmacy, appointed by the board.
(e) A representative of the board of nursing, appointed by the board.
(f) A representative of the board of medicine, appointed by the board.
(g) A representative of the New Hampshire Medical Society, appointed by the society.
(h) A representative of the New Hampshire Hospital Association, appointed by the association.
(i) A representative of the New Hampshire Nurse Practitioners Association, appointed by the association.
(j) A representative of the New Hampshire Pharmacist Association, appointed by the association.
(k) Two members of the public, one of whom shall be appointed by the senate president and one of whom shall be appointed by the speaker of the house of representatives.
II. Legislative members of the commission shall receive mileage at the legislative rate when attending to the duties of the commission.
III. The commission shall examine national data on the use of Ivermectin to treat Covid-19, relevant studies around the use of Ivermectin and work already being conducted by other states standing orders. The commission shall review implementation of RSA 318:47-n, permitting pharmacists to dispense Ivermectin by means of a standing order, and provide a recommendation as to whether such authority should be made permanent.
IV. The members of the study commission shall elect a chairperson from among the members. The first meeting of the commission shall be called by the senate member. The first meeting of the commission shall be held within 45 days of the effective date of this section. A majority of commission members shall constitute a quorum.
V. The commission shall report its findings and any recommendations for proposed legislation to the president of the senate, the speaker of the house of representatives, the senate clerk, the house clerk, the governor, and the state library on or before November 1, 2023.
6 Repeal. The following are repealed:
I. RSA 126-A:98 and the subdivision heading preceding RSA 126-A:98, relative to a commission to study the use of Ivermectin to treat Covid-19.
II. RSA 318:47-n, authorizing pharmacists to dispense Ivermectin by means of a standing order.
I. Paragraph I of section 6 of this act shall take effect December 31, 2023.
II. Paragraph II of section 6 of this act shall take effect July 1, 2024.
III. Sections 1-4 of this act shall take effect 60 days after its passage.
IV. The remainder of this act shall take effect upon its passage.
2022-1867s
AMENDED ANALYSIS
This bill allows pharmacists to dispense Ivermectin pursuant to a standing order. The authority is repealed July 1, 2024. The bill also establishes a commission to study the use of Ivermectin to treat Covid-19 and to provide a recommendation regarding whether to make the standing order permanent.